Ignite Creation Date:
2025-12-25 @ 3:11 AM
Ignite Modification Date:
2026-02-23 @ 9:22 PM
Study NCT ID:
NCT02169505
Status:
TERMINATED
Last Update Posted:
2019-11-27
First Post:
2014-06-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Lymphoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Lymphoma | View |
| None | Hodgkin lymphoma | View |
| None | HL | View |
| None | CD30 positive Hodgkin Lymphoma | View |
| None | Anaplastic large cell lymphoma | View |
| None | ALCL | View |
| None | Allogeneic Stem Cell Transplantation | View |
| None | ASCT | View |
| None | Graft-versus-host disease | View |
| None | GVHD | View |
| None | Brentuximab Vedotin | View |
| None | SGN-35 | View |
| None | Adcetris | View |